8-K: Celcuity Inc. Reports Third Quarter 2024 Financial Results and Provides Clinical Trial Update

Celcuity Inc. announced its third quarter 2024 financial results, highlighted by the full enrollment of the PIK3CA wild-type cohort in the VIKTORIA-1 trial and a strong cash position.

Summary

• Celcuity Inc. reported a net loss of $29.8 million, or $0.70 per share, for the third quarter of 2024, compared to a net loss of $18.4 million, or $0.83 per share, for the same period in 2023.
• The company's total operating expenses increased to $30.1 million, up from $18.9 million in the third quarter of 2023, with research and development expenses accounting for $27.6 million of the total.
• The PIK3CA wild-type cohort of the Phase 3 VIKTORIA-1 trial is fully enrolled, and topline data is expected in late Q1 2025 or Q2 2025.
• Celcuity had approximately $264 million in cash, cash equivalents, and investments at the end of Q3 2024, which is expected to fund current clinical development program activities through 2026.
• The company's Phase 1b/2 trial evaluating gedatolisib in combination with darolutamide for prostate cancer is ongoing, with preliminary data expected in Q2 2025.
• The VIKTORIA-2 Phase 3 clinical trial is on track to enroll its first patient in Q2 2025.

Sentiment

Score: 5

Explanation: The sentiment is neutral. While the company has made progress in its clinical trials and has a strong cash position, the increased net loss and operating expenses are concerning. The company is on track with its clinical trials, but the financial results are worse than the previous year.

Positives

• The company has a strong cash position of approximately $264 million, which is expected to fund operations through 2026.
• The PIK3CA wild-type cohort of the VIKTORIA-1 trial is fully enrolled, indicating progress in clinical development.
• The VIKTORIA-2 Phase 3 trial is on track to begin enrolling patients in Q2 2025.
• Celcuity is presenting additional nonclinical data at the San Antonio Breast Cancer Symposium, highlighting the mechanism of action of gedatolisib.

Negatives

• The company reported a net loss of $29.8 million for the third quarter of 2024, which is an increase from the $18.4 million loss in the same period of 2023.
• Operating expenses increased significantly to $30.1 million in Q3 2024, compared to $18.9 million in Q3 2023.
• Research and development expenses increased by approximately $10.1 million year-over-year.

Risks

• The company's clinical trials could face unforeseen delays, which could impact the timeline for data releases and regulatory approvals.
• There is a risk that the company may not be able to obtain and maintain regulatory approvals to commercialize its products.
• The market acceptance of Celcuity's products is uncertain, and there is a risk of competition from other therapies and tools.
• The company's ability to access capital on favorable terms or at all is a risk factor.

Future Outlook

The company expects to report topline data for the PIK3CA wild-type cohort of the VIKTORIA-1 trial in late Q1 2025 or during Q2 2025 and for the PIK3CA mutant cohort in the second half of 2025. The company also expects to begin enrolling patients in the VIKTORIA-2 trial in Q2 2025 and report preliminary data from the prostate cancer trial in Q2 2025. The current cash position is expected to fund operations through 2026.

Management Comments

• Brian Sullivan, CEO and co-founder of Celcuity, stated that enrollment in the VIKTORIA-1 study remains robust and on-track.
• Management believes non-GAAP adjusted net loss better enables Celcuity to focus on cash used in operations.

Industry Context

This announcement is relevant to the biotechnology industry, particularly companies focused on oncology drug development. The progress of Celcuity's clinical trials and its financial position are key indicators of its potential in the competitive landscape of targeted cancer therapies. The focus on PI3K and mTOR inhibitors is a common area of research in oncology.

Comparison to Industry Standards

• Celcuity's cash position of $264 million is relatively strong for a clinical-stage biotech company, providing a runway to fund operations through 2026. This compares favorably to other companies in the sector that may need to raise capital more frequently.
• The increase in R&D expenses is typical for a company advancing multiple clinical trials, such as the VIKTORIA-1 and VIKTORIA-2 trials. This is comparable to other companies in similar stages of development, such as Arcus Biosciences and Blueprint Medicines.
• The timeline for topline data from the VIKTORIA-1 trial is consistent with the typical timelines for Phase 3 trials in oncology. Companies like Exelixis and Clovis Oncology have reported similar timelines for their pivotal trials.
• The focus on PI3K and mTOR inhibitors is a common area of research in oncology, with companies like Novartis and Roche also developing therapies in this space. Celcuity's approach with gedatolisib, a pan-PI3K and mTOR inhibitor, is differentiated from single-node inhibitors.

Stakeholder Impact

• Shareholders may be concerned about the increased net loss, but encouraged by the progress in clinical trials and the strong cash position.
• Employees may be impacted by the increased operating expenses, but the company's financial stability should provide job security.
• Customers (patients) may benefit from the potential development of new cancer therapies.
• Suppliers and creditors may be reassured by the company's strong cash position.

Next Steps

• Celcuity will report topline data for the PIK3CA wild-type cohort of the VIKTORIA-1 trial in late Q1 2025 or Q2 2025.
• The company will present overall survival data from the B2151009 Phase 1b clinical trial at the San Antonio Breast Cancer Symposium in December 2024.
• Celcuity will begin enrolling patients in the VIKTORIA-2 Phase 3 clinical trial in Q2 2025.
• The company will report preliminary data from the Phase 1b/2 trial for prostate cancer in Q2 2025.

Key Dates

Keywords

Celcuity, gedatolisib, VIKTORIA-1, VIKTORIA-2, breast cancer, prostate cancer, clinical trial, oncology, PIK3CA, HR+, HER2-, financial results, biotechnology